PGHL5,435.00

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹9,022 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
30/06/2024
FY26
30/06/2025
FY27
30/06/2026
Inventory Days (DIO)137.22668.88495.89
Receivable Days (DSO)27.0591.9585.63
Payable Days (DPO)210.02
Cash Conversion Cycle (days)-45.75
Working Capital Turnover3.89
Asset Turnover1.450.430.46
Cash Conversion (CFO/Net Income)1.14
CFO/EBITDA0.75
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.